Keyword: biosimilars

64 results found
Copyright_dmitrydemidovich_123RF

An article on how employers can close the pension gap among BIPOC employees was the most-read story on BenefitsCanada.com over the last week. Here are the five most popular news stories of the week: 1. Employers can leverage choice, education to help close pension gap among BIPOC workers 2. Ontario biosimilars policy could cut drug costs for plan […]

  • By: Staff
  • February 17, 2023 February 16, 2023
  • 09:00

Changes to Ontario’s policy on the use of biosimilars in its public drug plan could result in savings for private benefits plans if they choose to follow the provincial model, says Theresa Tran, a principal in group benefits at Eckler Ltd. Starting March 31, Ontario Drug Benefit recipients who are on an originator biologic will […]

  • By: Blake Wolfe
  • February 16, 2023 February 15, 2023
  • 09:00

With the cost of drug claims continuing to rise in 2021, benefits plan sponsors can enable certain drug programs to curb costs, keeping their plans sustainable and offering the benefits that members highly value, said Lavina Viegas, director of pharmacy operations at Telus Health, during a session at Benefits Canada’s 2022 Face to Face Drug […]

The increasing use of high-cost medicines is the primary cost driver for all Canadian drug plans, according to a new report by the Patented Medicine Prices Review Board. It found drug costs for public plans rose by 5.3 per cent in 2019/20, with high-cost medicines accounting for 6.3 per cent of the increase. Among private […]

  • By: Staff
  • November 25, 2022 November 24, 2022
  • 09:00

The provision of employer-sponsored benefits has evolved significantly over the last 45 years, with the past decade ushering in the most consequential changes, fueled by technology, increased competition and demand. In the 80s and 90s, benefits plans were very siloed and one size fits all, says Chris Pryce, founder and president of Human Capital Benefits, […]

Total drug costs grew to $2 billion in 2021, rising steadily from $1.4 billion in 2017, according to Green Shield Canada’s annual drug trends report. The report, which is based on claims reported by Green Shield Canada, found the number of claimants also increased from 1.9 million to 2.1 million over the same period. While […]

  • By: Staff
  • September 23, 2022 September 22, 2022
  • 09:00

As the coronavirus pandemic continues, fewer Canadian benefits plan members are making drug claims, according to Telus Health’s annual drug trends report. The report, based on the drug claims activity of more than 10 million plan members in 2021, found just 56 per cent made a claim in 2021, reflecting a decreased frequency of in-person […]

  • By: Staff
  • June 23, 2022 June 22, 2022
  • 09:00
Copyright_Wavebreak Media Ltd_123RF

Changes to Quebec’s policy on the use of biosimilars in its public drug plan could result in savings for private benefits plans, says one expert. On April 13, 2022, the Régie de l’assurance maladie du Québec will delist certain biologic drugs from its formulary, requiring patients covered by the plan to switch to a biosimilar […]

This month marks the second anniversary of the beginning of the coronavirus pandemic, a 24-month span that has had profound effects on the health of benefits plan members and the status and structure of their plans. For drug plans in particular, several trends have come to light — or have accelerated — during the course […]

Copyright_Aleksandr Kalugin_123RF

In 2020, Canada Life Assurance Co. saw a decrease in the number of benefits plan members making a drug claim, though the costs of those claims were higher, according to Barb Martinez, the insurer’s national practice leader in drug solutions, speaking during a session at Benefits Canada‘s Face to Face in Drug Plan Management Forum […]